← Browse by Condition
Medical Condition
b cell acute lymphoblastic leukemia
Total Trials
7
Recruiting Now
7
Trial Phases
Phase 3, Phase 2, Phase 1
Leukemia clinical trials cover acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), and chronic lymphocytic leukemia (CLL) — distinct diseases with profoundly different biology and treatment approaches. AML research focuses on targeted agents for FLT3, IDH1/2, and TP53-mutated disease, while CLL trials explore fixed-duration venetoclax combinations that achieve treatment-free remissions.
Active trials investigate menin inhibitors for NPM1/KMT2A AML, magrolimab (anti-CD47) combinations, bispecific antibodies in relapsed ALL, and next-generation BTK inhibitors (pirtobrutinib) for ibrutinib-resistant CLL. MRD (minimal residual disease) negativity is emerging as a regulatory endpoint to accelerate approvals.
Frequently Asked Questions — b cell acute lymphoblastic leukemia Clinical Trials
How many clinical trials are currently recruiting for b cell acute lymphoblastic leukemia?
ClinicalMetric currently tracks 7 actively recruiting clinical trials for b cell acute lymphoblastic leukemia, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 7. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for b cell acute lymphoblastic leukemia?
b cell acute lymphoblastic leukemia research spans Phase 1 (4 trials), Phase 2 (1 trial), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a b cell acute lymphoblastic leukemia clinical trial?
Eligibility criteria for b cell acute lymphoblastic leukemia trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1 4
Phase 2 1
Phase 3 1
Top Sponsors
1 trial
1 trial
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT04094311 Phase 3
Recruiting
Study of Out of Specification for Tisagenlecleucel
Enrollment
200 pts
Location
Canada, Japan
Sponsor
Novartis Pharmaceuticals
NCT05648019 Phase 2
Recruiting
CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol
Enrollment
40 pts
Location
Singapore
Sponsor
KK Women's and Children's Hosp...
NCT05210907 Phase 1
Recruiting
Clinical Study of Hospital-manufactured CD19 CAR-T in Children and Adolescents With Acute Lymphoblastic Leukemia
Enrollment
5 pts
Location
South Korea
Sponsor
Seoul National University Hosp...
NCT03666000 Phase 1
Recruiting
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
Enrollment
135 pts
Location
United States, Austr...
Sponsor
Imugene Limited
NCT06343090
Recruiting
Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients
Enrollment
353 pts
Location
China
Sponsor
Beijing GoBroad Hospital
NCT06034275 Phase 1
Recruiting
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
Enrollment
36 pts
Location
United States
Sponsor
Vincerx Pharma, Inc.
NCT06793241 EARLY_Phase 1
Recruiting
Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic Leukemia
Enrollment
15 pts
Location
China
Sponsor
Zhejiang University
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology